JLPC has obtained the drug registration certificate for Famotidine Injection
I'm PortAI, I can summarize articles.
JLPC recently obtained the "Drug Registration Certificate" for Famotidine Injection approved by the National Medical Products Administration. This medication treats by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists. The acquisition of this certificate enriches the company's product line and enhances market competitiveness, but it is expected to have no significant impact on recent operating performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments